 SUNNYVALE, Calif., April 29, 2021 PRNewswire -- Accuray Incorporated NASDAQ: ARAY announced today that Accuray customers took the top two positions in the MArkerless Lung Target Tracking CHallenge MATCH experimental branch using the Accuray Synchrony Lung Tracking with Respiratory Modeling on the Radixact next-generation TomoTherapy platform, and CyberKnife System, respectively. 